Professional
Added to YB: 2025-02-12
Pitch date: 2025-02-09
CPH.TO [bullish]
Cipher Pharmaceuticals Inc.
+43.62%
current return
Author Info
No bio for this author
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 330.8M
Pitch Price
CAD 13.32
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.65
P/E
12.45
EV/Sales
6.52
Sector
Pharmaceuticals
Category
special_situation
Donville Kent Asset Management Portfolio Holding: Cipher Pharmaceuticals Inc.
CPH.TO: Acquired Natroba rights & US sales force, doubling biz size. Plan to bring out-licensed drugs in-house, boosting earnings & sales efficiency. Seeking Natroba approval in Canada & global licensing. Potential tuck-in M&A in 2025. Expect higher growth & profitability than market anticipates.
Read full article (1 min)